Table 1.
Patient characteristics
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | ||
|---|---|---|---|---|---|
| Patient characteristics | Age (years) | 51 | 34 | 42 | 56 |
| Gender | F | F | F | F | |
| BMI (kg/m2) | 35,4 | 20,7 | 26,1 | 34,2 | |
| Comorbidity | HBP | – | – | – | |
| Before esketamine initiation | Initial MADRS | 34 | 26 | 20 | 30 |
| Antidepressants | 9 | 6 | 4 | 4 | |
| During esketamine exposition | Anxiolytics | 3 | 2 | 2 | 1 |
| Antipsychotics | 1 | 1 | 2 | 1 | |
| Mood stabilisers | 0 | 0 | 0 | 1 | |
| Associated antidepressants | Amytriptiline Duloxétine | Paroxétine | Sertraline Miansérine | Duloxétine |
F, female; BMI, body mass index; HBP, high blood pressure; Initial MADRS, Montgomery–Åsberg Depression Rating Scale score before esketamine introduction; Antidepressants, number of antidepressants failures; Anxiolytics: number of anxiolytics associated with esketamine; Antipsychotics, number of antipsychotics associated with esketamine; Mood stabilisers, number of mood stabilisers associated with esketamine.